Ayan Mukerji’s Brahmastra has been in the making from the past few years. The movie was supposed to release in 2019, and then the makers postponed it to Summer 2020. A few months ago, they announced that it will hit the screens on 4th December 2020. However, due to the pandemic, the shooting of the film has been stalled, and once again it will get delayed.
According to a report in Mid-day, the makers are planning to resume the shoot in October and are eyeing on June 2021 release. A source told the tabloid, "If the crisis is relatively under control, and things go as planned, the film will go back on floors in October. Ayan has broken down the shoot into two shifts — 9 am to 2 pm, followed by another from 4 pm to 9 pm. There will be two separate minimal crews for the stints, with each unit adhering to on-set safety guidelines. Since producer Karan Johar is eyeing a June 2021 release, Ayan wants to wrap up the shoot latest by December."
The movie stars Amitabh Bachchan, Ranbir Kapoor, Alia Bhatt, Nagarjuna, Mouni Roy and Gurfateh Pirzada. Reportedly, Ayan has to shoot scenes with Big B, Alia, and Mouni.
However, according to the new guidelines actors above the age of 65 years old are not allowed to be on the sets. Also, Big B has tested positive for COVID-19, so we wonder if he will resume work anytime soon. There’s also a theme song shoot left which will be picturized on Ranbir.
Well, let’s hope that soon the shooting of the film gets completed and it hits the big screen. We are sure fans of Ranbir have been eagerly waiting for the movie.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.